PRME

Prime Medicine, Inc. (PRME) | Rumor.io

Prime Medicine

PRME

Attention (50-day avg)0.01%

Attention rank (50-day avg)#436

Bullish sentiment (50-day avg)79%

Price to earnings ratio-2.13

Market capitalization521.5M

Earnings per share-1.05

Dividend yield (TTM)—

Revenue (annual)4.6M

Net income (annual)-201.1M

Social

What share of all stock conversation is about PRME?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.02% +0.01	0.01% +0	0.01% 0

Sep 25

Prime Medicine's CEO Allan Reine explains the significance of the company's cleared Investigational New Drug (IND) application for PM647, an in vivo candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
The FDA has cleared Prime Medicine's IND application for AATD, with the company's gene-editing technology entering the in vivo clinical stage with two programs: Wilson disease and AATD.
Prime Medicine is expected to release first clinical data in 2027, with the company's stock price experiencing a significant increase in pre-market trading following the FDA's clearance of its IND application.

Generated by AI

Sentiment

Of the messages about PRME that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	75.06% -7.61	72.71% -19.86	85.69% -0.64
Bearish	0% 0	24.94% +7.61	27.29% +19.86	14.31% +0.64

Bullish· Jul 8

$PRME is poised to become the leading gene editing platform for rare diseases, with a potential "generational opportunity".
The company's partnerships, particularly with BMS, are expected to increase in the next 1-3 years, helping to fund its life-changing technology.
$PRME has cleared a significant regulatory hurdle, with New Zealand's Medsafe granting the company's first-ever clinical authorization for an in vivo Prime Editing therapy, setting the stage for potential upside of over 100% from the current price.

Bearish· Oct 22

The removal of Prime Medicine's CEO was not a significant issue, but the shelving of the CGD program due to its small total addressable market (TAM) is a major concern, as it means the company won't have human data until 2027.
Some individuals who previously promoted Prime Medicine are now calling it a fraud, with one person even claiming to have shown the world the stock first while having no position in it.
Prime Medicine's price is experiencing significant volatility, with a 20% drop from its high yesterday, and some individuals are warning of further declines, with one even joking that they'll sell their shares "from my cold dead hands".

Generated by AI

Topics

Of the messages about PRME that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	98.09%	96.73%	77.11%
Technical Analysis	—	1.67%	3.14%	8.87%
Analysts	—	0.24%	0.13%	7.45%
Controversies	—	0%	0%	4.82%
Macro	—	0%	0%	1.29%
Earnings	—	0%	0%	0.46%

Jul 8

The arbitration tribunal declared that PM647 falls within Prime Medicine's "Field" as defined by the 2019 Collaboration and License Agreement, confirming Prime Medicine did not breach the agreement.
The tribunal confirmed that PM647 is within Prime Medicine's contractual "Field", clearing the path for the program and allowing Prime Medicine to develop and commercialize PM647 in Alpha-1 Antitrypsin Deficiency (AATD).
The arbitration win clears a major legal overhang for Prime Medicine, with the stock surging approximately 17% in response, and the company now pricing in a cleaner setup for the gene-editing pipeline.

Generated by AI

Community

Of the messages about PRME, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	62.5%	90.23%	88.24%	82.2%
Newcomers	37.5%	9.77%	11.76%	17.8%

Regulars· Sep 25

Prime Medicine's CEO Allan Reine explains the significance of the FDA's clearance of its IND application for PM647, an in vivo candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
The company's gene-editing technology is entering the in vivo clinical stage with two programs: Wilson disease and AATD, following the FDA's recent acceptance of its IND, with first clinical data expected in 2027.
The FDA's clearance of Prime Medicine's IND application for AATD gene editing therapy has led to a significant price increase, with the stock jumping ~8% pre-market.

Newcomers· Sep 25

Prime Medicine, Inc. ($PRME) announced FDA clearance of the Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency, leading to a significant stock price increase.
The company's modular platform and universal liver LNP technology have enabled quick progress on multiple programs, with initial clinical data expected in 2027, despite being down around 12% for the year.
The stock price has been volatile, with shares running ~13% higher after hours to $3.47, but then fading to around $3.09 at last check, with some investors expressing concerns about the company's cash reserves and ability to fund its plans.

Generated by AI

News

Citizens reiterates Prime Medicine stock rating on gene editing capabilities

2d agoInvesting.com

Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)

Prime Medicine, Inc. maintains a Buy rating, supported by an advancing prime editing pipeline and multiple upcoming clinical catalysts. Click for a PRME update.

4d agoSeeking Alpha

Prime Medicine Gets FDA Green Light for Gene Editing Study - Prime Medicine (NASDAQ:PRME)

The FDA clears Prime Medicine’s IND application for PM647, an investigational in vivo Prime Editor for AATD, for human trials.

4d agoBenzinga

Prime Medicine stock holds at outperform on FDA IND clearance

5d agoInvesting.com

12 Health Care Stocks Moving In Thursday's After-Market Session - Prime Medicine (NASDAQ:PRME), Onconetix

Gainers Prime Medicine (NASDAQ:PRME) shares increased by 13.0% to $3.47 during Thursday's after-market session. The market value of their outstanding shares is at $567.7 million. Onconetix (NASDAQ:ONCO) stock rose

5d agoBenzinga

Why is Prime Medicine stock surging today?

5d agoInvesting.com

Also Discussed

Investors talking about PRME also mention

#	Name	Attention
1	Beam Therapeutics IncBEAM	0.02%+0.02
2	Intellia Therapeutics, Inc.NTLA	0%+0
3	Caribou Biosciences, Inc.CRBU	0%new
4	CRISPR Therapeutics AGCRSP	0%-0.01
5	VERV - Verve Therapeutics, Inc.	——
6	Century Therapeutics IncIPSC	0%0
7	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
8	Editas Medicine, Inc.EDIT	0%+0
9	AbCellera Biologics Inc.ABCL	0.24%-0.06
10	Wave Life Sciences Ltd.WVE	0%+0

Prime Medicine, Inc.

Healthcare
Biotechnology

Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA. The company is building therapies intended to address diseases caused by defined genetic alterations, with research programs spanning hematology, immunology and oncology, liver, lung, ocular, and neuromuscular conditions. Its current work centers on investigational, pre-commercial product candidates and platform capabilities that support targeted genetic correction across multiple tissues and disease areas. Prime Medicine, Inc. plays a specialized role in the broader genetic medicines market by advancing next-generation editing approaches aimed at expanding the reach of precision therapeutics for serious inherited and acquired diseases.

Website

Location

60 First Street

Cambridge, MA, 02141

United States

Social

What share of all stock conversation is about PRME?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.02% +0.01	0.01% +0	0.01% 0

Sep 25

Prime Medicine's CEO Allan Reine explains the significance of the company's cleared Investigational New Drug (IND) application for PM647, an in vivo candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
The FDA has cleared Prime Medicine's IND application for AATD, with the company's gene-editing technology entering the in vivo clinical stage with two programs: Wilson disease and AATD.
Prime Medicine is expected to release first clinical data in 2027, with the company's stock price experiencing a significant increase in pre-market trading following the FDA's clearance of its IND application.

Generated by AI

Sentiment

Of the messages about PRME that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	75.06% -7.61	72.71% -19.86	85.69% -0.64
Bearish	0% 0	24.94% +7.61	27.29% +19.86	14.31% +0.64

Bullish· Jul 8

$PRME is poised to become the leading gene editing platform for rare diseases, with a potential "generational opportunity".
The company's partnerships, particularly with BMS, are expected to increase in the next 1-3 years, helping to fund its life-changing technology.
$PRME has cleared a significant regulatory hurdle, with New Zealand's Medsafe granting the company's first-ever clinical authorization for an in vivo Prime Editing therapy, setting the stage for potential upside of over 100% from the current price.

Bearish· Oct 22

The removal of Prime Medicine's CEO was not a significant issue, but the shelving of the CGD program due to its small total addressable market (TAM) is a major concern, as it means the company won't have human data until 2027.
Some individuals who previously promoted Prime Medicine are now calling it a fraud, with one person even claiming to have shown the world the stock first while having no position in it.
Prime Medicine's price is experiencing significant volatility, with a 20% drop from its high yesterday, and some individuals are warning of further declines, with one even joking that they'll sell their shares "from my cold dead hands".

Generated by AI

Topics

Of the messages about PRME that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	98.09%	96.73%	77.11%
Technical Analysis	—	1.67%	3.14%	8.87%
Analysts	—	0.24%	0.13%	7.45%
Controversies	—	0%	0%	4.82%
Macro	—	0%	0%	1.29%
Earnings	—	0%	0%	0.46%

Jul 8

The arbitration tribunal declared that PM647 falls within Prime Medicine's "Field" as defined by the 2019 Collaboration and License Agreement, confirming Prime Medicine did not breach the agreement.
The tribunal confirmed that PM647 is within Prime Medicine's contractual "Field", clearing the path for the program and allowing Prime Medicine to develop and commercialize PM647 in Alpha-1 Antitrypsin Deficiency (AATD).
The arbitration win clears a major legal overhang for Prime Medicine, with the stock surging approximately 17% in response, and the company now pricing in a cleaner setup for the gene-editing pipeline.

Generated by AI

Community

Of the messages about PRME, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	62.5%	90.23%	88.24%	82.2%
Newcomers	37.5%	9.77%	11.76%	17.8%

Regulars· Sep 25

Prime Medicine's CEO Allan Reine explains the significance of the FDA's clearance of its IND application for PM647, an in vivo candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
The company's gene-editing technology is entering the in vivo clinical stage with two programs: Wilson disease and AATD, following the FDA's recent acceptance of its IND, with first clinical data expected in 2027.
The FDA's clearance of Prime Medicine's IND application for AATD gene editing therapy has led to a significant price increase, with the stock jumping ~8% pre-market.

Newcomers· Sep 25

Prime Medicine, Inc. ($PRME) announced FDA clearance of the Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency, leading to a significant stock price increase.
The company's modular platform and universal liver LNP technology have enabled quick progress on multiple programs, with initial clinical data expected in 2027, despite being down around 12% for the year.
The stock price has been volatile, with shares running ~13% higher after hours to $3.47, but then fading to around $3.09 at last check, with some investors expressing concerns about the company's cash reserves and ability to fund its plans.

Generated by AI

Prime Medicine

Social

Sep 25

Bullish· Jul 8

Bearish· Oct 22

Jul 8

Regulars· Sep 25

Newcomers· Sep 25

Citizens reiterates Prime Medicine stock rating on gene editing capabilities

Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)

Prime Medicine Gets FDA Green Light for Gene Editing Study - Prime Medicine (NASDAQ:PRME)

Prime Medicine stock holds at outperform on FDA IND clearance

12 Health Care Stocks Moving In Thursday's After-Market Session - Prime Medicine (NASDAQ:PRME), Onconetix

Why is Prime Medicine stock surging today?

Also Discussed

Prime Medicine, Inc.

Company Information

Location

Citizens reiterates Prime Medicine stock rating on gene editing capabilities

Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)

Prime Medicine Gets FDA Green Light for Gene Editing Study - Prime Medicine (NASDAQ:PRME)

Prime Medicine stock holds at outperform on FDA IND clearance

12 Health Care Stocks Moving In Thursday's After-Market Session - Prime Medicine (NASDAQ:PRME), Onconetix

Why is Prime Medicine stock surging today?

Also Discussed

Social

Sep 25

Bullish· Jul 8

Bearish· Oct 22

Jul 8

Regulars· Sep 25

Newcomers· Sep 25